{"title":"Prostacyclin Assists in the Repair of Ruptured Amnions through the Proliferation and Migration of Amnion Mesenchymal Cells.","authors":"Masahito Takakura, Yosuke Kawamura, Yusuke Ueda, Sunao Matsuzaka, Eriko Yasuda, Yu Matsuzaka, Asako Inohaya, Yoshitsugu Chigusa, Masaki Mandai, Shuh Narumiya, Koh-Ichi Yuhki, Haruta Mogami","doi":"10.1016/j.ajpath.2025.06.002","DOIUrl":null,"url":null,"abstract":"<p><p>Preterm prelabor rupture of membrane (pPROM) is a risk factor for preterm birth. However, spontaneous healing of ruptured fetal membranes is occasionally clinically observed. Prostaglandins are involved in the wound-healing process in various tissues. Here, the roles of prostacyclin (PGI<sub>2</sub>) in the repair of fetal membranes were investigated in a mouse model. Ptgs1, Ptgs2, Ptgis mRNA, and PGI<sub>2</sub> were increased in the ruptured murine fetal membranes. Compared with the number of amnion mesenchymal cells at the intact site, the number of these cells at the rupture site was greater, and PGI<sub>2</sub> synthase was increased in the mesenchymal cells of the amnion. Repair of the ruptured amnion was compromised by treatment with a PGI<sub>2</sub> receptor (IP) antagonist, which decreased proliferation of the amnion mesenchymal cells. In contrast, an IP agonist partially restored repair of the amnion under the suppression of prostaglandin synthesis by a cyclooxygenase inhibitor. Compared with that in wild-type fetuses, the repair of the ruptured amnion in IP-deficient fetuses was compromised, with fewer proliferations of amnion mesenchymal cells observed at the rupture site. In vitro, the proliferation and migration of cultured human amnion mesenchymal cells were stimulated by an IP agonist and inhibited by an IP antagonist. These findings suggest that PGI<sub>2</sub> facilitates amnion repair by promoting the proliferation and migration of amnion mesenchymal cells.</p>","PeriodicalId":7623,"journal":{"name":"American Journal of Pathology","volume":" ","pages":""},"PeriodicalIF":4.7000,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Pathology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ajpath.2025.06.002","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Preterm prelabor rupture of membrane (pPROM) is a risk factor for preterm birth. However, spontaneous healing of ruptured fetal membranes is occasionally clinically observed. Prostaglandins are involved in the wound-healing process in various tissues. Here, the roles of prostacyclin (PGI2) in the repair of fetal membranes were investigated in a mouse model. Ptgs1, Ptgs2, Ptgis mRNA, and PGI2 were increased in the ruptured murine fetal membranes. Compared with the number of amnion mesenchymal cells at the intact site, the number of these cells at the rupture site was greater, and PGI2 synthase was increased in the mesenchymal cells of the amnion. Repair of the ruptured amnion was compromised by treatment with a PGI2 receptor (IP) antagonist, which decreased proliferation of the amnion mesenchymal cells. In contrast, an IP agonist partially restored repair of the amnion under the suppression of prostaglandin synthesis by a cyclooxygenase inhibitor. Compared with that in wild-type fetuses, the repair of the ruptured amnion in IP-deficient fetuses was compromised, with fewer proliferations of amnion mesenchymal cells observed at the rupture site. In vitro, the proliferation and migration of cultured human amnion mesenchymal cells were stimulated by an IP agonist and inhibited by an IP antagonist. These findings suggest that PGI2 facilitates amnion repair by promoting the proliferation and migration of amnion mesenchymal cells.
期刊介绍:
The American Journal of Pathology, official journal of the American Society for Investigative Pathology, published by Elsevier, Inc., seeks high-quality original research reports, reviews, and commentaries related to the molecular and cellular basis of disease. The editors will consider basic, translational, and clinical investigations that directly address mechanisms of pathogenesis or provide a foundation for future mechanistic inquiries. Examples of such foundational investigations include data mining, identification of biomarkers, molecular pathology, and discovery research. Foundational studies that incorporate deep learning and artificial intelligence are also welcome. High priority is given to studies of human disease and relevant experimental models using molecular, cellular, and organismal approaches.